|
Volumn 53, Issue 9, 2000, Pages 593-608
|
In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC
a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CIPROFLOXACIN;
FLEROXACIN;
LEVOFLOXACIN;
METICILLIN;
NORFLOXACIN;
OFLOXACIN;
PRULIFLOXACIN;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
SPARFLOXACIN;
TOSUFLOXACIN;
ANTIBACTERIAL ACTIVITY;
ANTIBIOTIC SENSITIVITY;
ARTICLE;
BACTERICIDAL ACTIVITY;
CITROBACTER FREUNDII;
ENTEROBACTERIACEAE;
GRAM NEGATIVE BACTERIUM;
GRAM POSITIVE BACTERIUM;
MINIMUM INHIBITORY CONCENTRATION;
NONHUMAN;
PSEUDOMONAS AERUGINOSA;
SERRATIA MARCESCENS;
STAPHYLOCOCCUS AUREUS;
STREPTOCOCCUS PNEUMONIAE;
ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE;
BACTERIA;
COMPARATIVE STUDY;
DIOXOLANES;
DRUG RESISTANCE, MICROBIAL;
ENGLISH ABSTRACT;
HUMAN;
OFLOXACIN;
PIPERAZINES;
QUINOLONES;
RESPIRATORY TRACT INFECTIONS;
SEPSIS;
|
EID: 0033774226
PISSN: 03682781
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (5)
|
References (18)
|